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Immunoreactivity to endothelin was detected inconditioned culture medium from both canine and porcine tracheal epith- 
elial cells. Gel permeation chromatography and fast protein liquid chromatography were used to confirm the identity 
of the endothelin. The two peaks demonstrated on fast protein liquid chromatography co-eluted with endothelin 1 and 
endothelin 3 respectively. 
Endothelin; (Airway epithelial cell) 
1. INTRODUCTION 
Endothelin is a potent vasoconstrictor peptide 
which was first isolated from the conditioned 
medium of porcine aortic endothelial cells [1]. En- 
dothelin 1 contracts isolated blood vessels from 
different vascular beds in a variety of species [1,2]. 
It also promotes the release of prostaglandins from 
isolated lungs [3], endothelium-derived relaxing 
factor from blood vessels [3] and atrial natriuretic 
peptide from atrial myocytes [4] but inhibits the 
release of renin from isolated glomeruli [5]. In ad- 
dition it stimulates the proliferation of vascular 
smooth muscle [6]. Two other forms of endothelin 
have now been characterised. Endothelin 3 shares 
15 of its 21 residues with porcine endothelin and is 
also a potent vasoconstrictor [7]. 
More recently it has become apparent that endo- 
thelin can exert effects on the airways. Endothelin 
1 contracts isolated rat trachea [8] and when 
aerosolised it causes bronchoconstriction in 
anaesthetised and ventilated guinea-pigs [9]. 
Because there is evidence that airway epithelial cells 
can release constrictor substances [10] we have in- 
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vestigated the possibility that cultured airway epi- 
thelial cells form endothelin. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
Segments of canine trachea were obtained immediately after 
death. The segments were filled with digestion medium 
(143.4 mM Na +, 5.9 mM K +, 123.1 mM CI-, 1.2 mM H2PO~, 
5 mM HCOi, 5.9mM glucose, 20mM Hepes, 105 U/1 
penicillin, 100mg/l streptomycin, 100 mg/l gentamicin, 1070 
bovine serum albumin and 0.1 070 pronase), the ends were sealed 
with parafilm and the segments incubated at 4°C for 24 h. The 
digestion medium was then spun, the supernatant removed and 
the cell pellet resuspended in a 1:1 mixture of Ham's FI2 
medium and Dulbecco's Modified Eagle's Medium (with 
sodium pyruvate and 1000 mg/l glucose) containing 5070 foetal 
calf serum (FCS), 105 U/1 penicillin, 100 mg/l streptomycin, 
1CO mg/l gentamicin and 105 U/I mycostatin. The cell suspen- 
sion was then incubated at 37°C for 1 h in plastic wells to allow 
any contaminating fibroblasts to adhere to the plastic. The cell 
suspension was then removed and added to 25 cm 2 collagen- 
coated plastic flasks and incubated at 370C. Cells took 3-4 days 
to reach confluence. Once confluent cells were incubated with 
either serum-free medium or medium containing 5°7o FCS for 
48 h. Medium incubated at 37QC for 48 h in the absence of cells 
served as a control. Conditioned medium was stored at - 70°C 
until it was assayed. We confirmed that the cells were epithelial 
by performing immunohistochemical st ining using a mouse 
anti-human antibody for cytokeratin. 980/0 of the cells were 
positive for cytokeratin. In contrast we were unable to 
demonstrate any staining for Von Willebrand Factor using a 
mouse anti-human antibody known to cross-react with canine 
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tissue, showing that there was no evidence of contamination 
with endothelial cells. Porcine epithelial cells were cultured in 
the same way. 
Culture medium, foetal calf serum, penicillin-gentamicin and 
streptomycin were purchased from Gibco (Uxbridge, England). 
Mycostatin was obtained from E.R. Squibb and Sons 
(Hounslow, England) and pronase from Sigma (Poole, 
England). Monoclonal antibodies were purchased from Dako 
(High Wycombe, England). 
2.2. Extraction procedure 
Conditioned media were extracted on Sep-Pak C 18 cartridges 
(Waters Associates, CA, USA) following Sep-Pak activation by 
l0 ml acetonitrile, 10 ml methanol and then l0 ml of 4% (v/v) 
acetic acid. 8 ml of each sample were acidified with 4 ml of 4% 
acetic acid, loaded onto the cartridge and the cartridge washed 
with l0 ml of 4°70 acetic acid. Endothelin-like immunoreactivity 
was eluted with 2 ml of 60°70 (v/v) acetonitrile/water containing 
0.026 M ammonium acetate. The eluate was dried in a Savant 
vacuum centrifuge, the resulting pellet reconstituted with assay 
buffer and the aliquot assayed. With this extraction procedure 
the recovery of synthetic endothelin added to culture medium 
was 86 _+ 4% (n = 4). 
2.3. Radioimmunoassay 
The assay was performed in 60 mM phosphate buffer, pH 
7.4, containing l0 mM EDTA, 7 mM sodium azide and 0.3°70 
(w/v) bovine serum albumin. The antiserum raised in rabbits to 
endothelin 1 was obtained from the Peptide Institute, Osaka, 
Japan. It was used at a final dilution of 1 : 14000 and cross- 
reacted 30% with endothelin 3. Radiolabelled tracer was 
prepared by conventional chloramine-T oxidation and purified 
by HPLC. In a typical experiment 50 #l of endothelin solution 
(4 nmol) in 0.4 M phosphate buffer, pH 7.4, was added to 10/d 
(1 mCi) of Na125I. The reaction was initiated with 10/zl of 
0.5 mg/ml of chloramine-T and was stopped 10 s later by addi- 
tion of 25/zl of 2.4 ng/ml of sodium metabisulphite. The reac- 
tion mixture was diluted with 200/0 (by vol.) aqueous acetonitrite 
containing 0.1070 (by vol.) and trifluoroacetic acid (TFA) and 
loaded on a reverse phase Techsill 5 C18 column which was 
equilibrated with the same solution. Optimal separation of 
[~25I]endothelin was achieved by elution with an isocratic gra- 
dient of 36°70 aqueous acetonitrile/0.1 °70TFA. The endothelin 
tracer had a specific activity of 60 Bq/fmol as assessed by self 
displacement. Endothelin tracer (1800 cpm) and antiserum were 
added to each tube to a total volume of 700/zl and samples 
(10-100/zl) were assayed in duplicate. After 5 days incubation at 
4°C, antibody-bound and free fractions were separated by char- 
coal adsorption of the free fraction. The standard used was syn- 
thetic endothelin 1. The assay could detect changes of 
10 fmol/assay tube with 95% confidence and the intra- and 
inter-assay variation was less than 10%. 
2.4. Gel permeation and fast protein liquid chromatography 
Endothelin-like immunoreactivity was characterised by gel 
permeation chromatography on a column containing Sephadex 
G-25 (Pharmacia Chemicals, Uppsala, Sweden) and by fast pro- 
tein liquid chromatography with a PEPRPC HRS/5 reverse- 
phase C18 high resolution column (Pharmacia). Samples after 
being extracted and dried in a Savant vacuum centrifuge were 
reconstituted in phosphate buffer and were loaded onto the gel 
column (0.9 x 60 cm). This was eluted with 60 mM phosphate 
buffer, pH 7.4, containing 0.2 M sodium chloride, 10 mM 
EDTA, 7 mM sodium azide and 0.30/o (w/v) bovine serum 
albumin at 0.6 ml per 12 min per fraction. With each sample 
run, dextran blue 2000 (mol. wt. 2 x 106), cytochrome c (tool. 
wt. 12384) and Na1251 were included as markers for the void 
volume, molecular size and total volume. Samples of each frac- 
tion were assayed for endothelin immunoreactivity and the elu- 
tion fraction was determined. 
Samples for FPLC were reconstituted in water containing 
0.1%0 TFA, centrifuged in a microfuge and the supernatant 
loaded onto the column. This was equilibrated with 10%0 (v/v) 
of 10%0 (v/v) acetonitrile with 0.1o70 TFA, from 10070 to 45o70 
(v/v) in water over 1 h followed by an isocratic gradient of 45070 
(v/v) acetonitrile with 0.1%0 TFA for a further 10 min at 
1 ml/min per fraction. Samples of each fraction were assayed 
for endothelin-like immunoreactivity. Both columns were 
calibrated with synthetic endothelin before and after a series of 
sample runs. 
3. RESULTS AND DISCUSSION 
We have  detected  immunoreact ive  ndothe l in  in 
cond i t ioned  med ium f rom cu l tured  can ine  t rachea l  
ep i the l ia l  cells ( tab le  1). In  cont ras t ,  levels o f  endo-  
the l in  in cont ro l  med ium were be low the l imits  o f  
detect ion ,  regard less  o f  whether  the  med ium con-  
ta ined  foeta l  ca l f  serum or  not .  Nor  was there  any  
s ign i f i cant  d i f fe rence  between endothe l in  levels in 
cond i t ioned  med ium,  conta in ing  foeta l  ca l f  serum,  
and  med ium which  was serum- f ree .  These  f ind ings  
ind icate  that  the  endothe l in  was fo rmed by  the  epi- 
the l ia l  cells and  was not  a component  o f  foeta l  ca l f  
serum which  was added to the  med ium.  We have  
a lso  detected  immunoreact ive  endothe l in  
(45 pmol / l )  in poo led  med ium f rom 5 d i f fe rent  
cu l tu res  o f  porc ine  t rachea l  ep i the l ia l  cells. Ser ia l  
two- fo ld  d i lu t ion  curves  w i th  cond i t ioned  med ium 
and two immunoreact ive  peaks  e luted on  FPLC 
were  para l le l  w i th  a s tandard  curve  for  endothe l in  
( f ig. 1). 
We conf i rmed the  ident i ty  o f  the  immunoreac-  
t ive endothe l in  in the cond i t ioned  med ium f rom 
cu l tures  o f  can ine  t rachea l  ep i the l ium us ing gel 
permeat ion  chromatography  and  by  fast  p ro te in  li- 
Table 1 
Concentration of endothelin (pmol/l) in conditioned culture 
medium 
Control Conditioned medium Conditioned medium 
(n = 6) with FCS (n = 7) serum-free (n = 10) 
<2 285 _+ 48 240_+ 17 
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Fig. 1. A standard curve of endothelin 1 (open circles) and serial 
2-fold dilution curves of the conditioned medium extract of 
canine tracheal epithelial cells (e), the immunoreactive peak 
eluted in the position of endothelin 1 on FPLC (A) and the im- 
munoreactive p ak eluted in the position of endothelin 3 on 
FPLC (A). 
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Fig.2. (A) Sephadex G-25 column chromatography and (B) 
FPLC of the immunoreactive endothelin i  the conditioned 
medium of canine tracheal epithelial cells. ETI, ET3, the elution 
positions of endothelin 1 and endothelin 3,respectively; ACN, 
acetonitrite. 
quid chromatography (FPLC) (fig.2). A broad 
peak which co-eluted with endothelins 1and 3 was 
seen on gel permeation chromatography. Two 
peaks were demonstrated on FPLC. The first peak 
contained 25°70 of the immunoreactivity and co- 
eluted with endothelin 3. The rest of the immuno- 
reactivity was present in the second peak which co- 
eluted with endothelin 1. The antibody to endo- 
thelin 1 used in the radio-immunoassay had 30070 
cross-reactivity with endothelin 3. This means that 
similar amounts of endothelin 1 and endothelin 3
were in effect present in the culture supernatant. 
This is the first evidence that endothelin can be 
formed by non-endothelial cells. This finding is 
consistent with endothelin having actions outside 
the cardiovascular system. Certainly binding sites 
for endothelin are found not only in blood vessels 
but in a wide variety of tissues including the air- 
ways [11,12]. Cell culture, however, is an artificial 
situation and we do not yet know whether endo- 
thelin is formed in the airways in vivo. Indeed it 
could be argued that culturing cells on an artificial 
surface represents a form of cell injury. One of the 
characteristic features of asthma is epithelial injury 
and one could speculate that this is a situation 
where endothelin might be released from airway 
epithelial cells. However, although endothelin is a 
very potent vasoconstrictor agent, it is two orders 
of magnitude less potent in causing broncho- 
constriction. Threshold contractions for isolated 
trachea in the rat [8], guinea-pig, dog and pig (un- 
published observations) range from 10 -8 to 
10 -7 M. Nonetheless if endothelin were released in 
vivo, it is not impossible that concentrations of this 
magnitude could occur in the airways close to the 
smooth muscle. There is also evidence that in the 
guinea-pig endothelin causes bronchoconstriction 
through the release of secondary mediators uch as 
PAF and prostaglandins. I f this were the case in 
man, endothelin might cause bronchoconstriction 
more readily in patients with asthma whose airways 
are infiltrated with inflammatory cells capable of 
generating mediators such as PAF. Endothelin 
could also have other effects in the airways. There 
is evidence that it has anti- inflammatory actions 
[13]. It is also a mitogen for vascular smooth mus- 
cle but it remains to be seen whether it is a mitogen 
for airway smooth muscle. Further work will be 
necessary to determine whether endothelin is a 
mediator in asthma. 
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